News | January 10, 2022
Arch Pharmalabs signs agreement with Orchem Technologies to use SMB platform
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Biogen paid Ionis a US $ 60 million one-time upfront payment
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Partnering to build biosynthesis processes and a pharmaceutical production platform
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
Subscribe To Our Newsletter & Stay Updated
